From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment ...

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and ...

In an era of increasing regulatory complexity, life sciences organizations are modernizing GxP compliance through digital ...

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s ...

In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

Meanwhile, drugmakers ramp up U.S. manufacturing investments to navigate policy shifts and protect supply chain resilience.

This episode of Pharma Pulse examines how in-store pharmacies are evolving beyond prescriptions to deliver clinical services, ...